Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Tesamorelin vs GHRP-6

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin has stronger documented evidence (FDA-Approved) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tesamorelin

FDA-Approved

GHRP-6

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Tesamorelin GHRP-6
Class GHRH analog (FDA-approved) GHRP; ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion GHS-R1a agonist with strong orexigenic effect
Route SC injection SC / Intranasal
Half-life ~26 min ~15-30 min
Dosage (research) 2 mg SC daily (FDA label) 100-300 mcg SC 2-3x daily
Evidence tier FDA-Approved Anecdotal + Animal Studies
Research depth 127 indexed (PubMed 84 · CT 23 · EPMC 20) 163 indexed (PubMed 141 · CT 0 · EPMC 22)
Availability Prescription Research Chemical
Reported risks Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 Strong hunger; cortisol/prolactin rise; water retention

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tesamorelin or GHRP-6?

Tesamorelin has stronger documented evidence (FDA-Approved) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Tesamorelin and GHRP-6?

Tesamorelin is classed as GHRH analog (FDA-approved); GHRP-6 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; GHRP-6, GHS-R1a agonist with strong orexigenic effect. Reported half-life: Tesamorelin, ~26 min; GHRP-6, ~15-30 min. Routes in published studies: Tesamorelin, SC injection; GHRP-6, SC / Intranasal.

Which has stronger evidence, Tesamorelin or GHRP-6?

Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies.

Which is more accessible, Tesamorelin or GHRP-6?

Tesamorelin is FDA-approved and GHRP-6 is not. Catalog status: Tesamorelin, Prescription; GHRP-6, Research Chemical. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Tesamorelin and GHRP-6 ever combined?

Tesamorelin and GHRP-6 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…